Compass Health Analytics, Inc.

Business Insights

Titan Pharmaceuticals, Inc. | August 22, 2022

Titan Pharmaceuticals, Inc. announced that it has expanded its Board of Directors from five to eleven and appointed six new directors following their election at its special meeting of stockholders held on August 15, 2022. The new directors, which were on a nominee slate proposed by Activist Investing LLC are Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, David E. Lazar, Matthew C. McMurdo and David Natan. In addition, following the Special Meeting, Mr. Lazar was appointed int...

Pharma Tech

Daiichi | January 20, 2021

Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbusterland. The FDA cleared Enhertu for HER2-positive gastric or gastroesophageal junction cancer patients who previously received Roche’s standard-of-care Herceptin, the companies said Monday. An antibody-drug conjugate, Enhertu is the first HER2-directed therapy approved in gastric cancer in a decade, the companies said. And it earned the green ...

XTALKS | July 18, 2020

Commercial launch readiness is a critical stage in a product life cycle. While the world hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will only increase price pressures overall for the industry. The era of increasing competitive and price pressure is not going away and capturing full value from every product launch is critical. However, history shows that only a third of product launches meet analyst expectations. Teams with the ability to opt...

Business Insights

Adalvo | March 01, 2022

Adalvo, the leading global B2B pharmaceutical company, is thrilled to announce the recent establishment of a new entity ArphioTM a venture initiated in close collaboration with SK Pharma. Together with our new partner, we are developing a powerhouse, solely dedicated to orphan drugs with the intention of improving accessibility of vital treatments, to patients suffering from rare diseases and unmet medical needs. ArphioTM will operate as an independent entity, focus...